Go Pro
→ You’ve never seen anything like this before (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
OPTH
Optimi Health
$4.90
-3.4%		$4.78
$4.00
▼
$6.40
$28.08MN/A98,494 shs59,730 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$1.23
-3.9%		$1.26
$0.85
▼
$4.60
$5.89M1.31129,076 shs106,116 shs
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$1.73
-1.7%		$2.24
$1.50
▼
$43.65
$23.08M0.32872,341 shs126,467 shs
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$2.18
+0.9%		$2.09
$0.99
▼
$2.95
$25.22M0.6547,741 shs27,191 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
OPTH
Optimi Health
+6.51%+4.75%+5.85%+16.28%+506,999,900.00%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-0.78%-3.76%-1.54%+11.30%-71.11%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-3.83%-9.28%-7.37%-31.78%-94.79%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
0.00%+0.93%+4.35%-4.85%+100.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
OPTH
Optimi Health
$4.90
-3.4%		$4.78
$4.00
▼
$6.40
$28.08MN/A98,494 shs59,730 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$1.23
-3.9%		$1.26
$0.85
▼
$4.60
$5.89M1.31129,076 shs106,116 shs
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$1.73
-1.7%		$2.24
$1.50
▼
$43.65
$23.08M0.32872,341 shs126,467 shs
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$2.18
+0.9%		$2.09
$0.99
▼
$2.95
$25.22M0.6547,741 shs27,191 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
OPTH
Optimi Health
+6.51%+4.75%+5.85%+16.28%+506,999,900.00%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-0.78%-3.76%-1.54%+11.30%-71.11%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-3.83%-9.28%-7.37%-31.78%-94.79%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
0.00%+0.93%+4.35%-4.85%+100.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
OPTH
Optimi Health
1.50
ReduceN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.00
SellN/AN/A
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
2.78
Moderate Buy$18.00925.64% Upside
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest SNOA, OPTH, TVRD, and TXMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Lucid Cap Mkts logo
Lucid Cap Mkts
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/27/2026
OPTH
Optimi Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/26/2026
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D-)
8/21/2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/14/2026
OPTH
Optimi Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/12/2026
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D+)
8/7/2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/30/2026
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$5.00
7/24/2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/8/2026
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/8/2026
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform$10.00
(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
OPTH
Optimi Health
$290K95.83N/AN/AN/A∞
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$21.92M0.27N/AN/A$0.65 per share1.91
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$7.14M3.28N/AN/A$2.23 per share0.79
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$3.02M8.39$0.05 per share46.30$2.32 per share0.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
OPTH
Optimi Health
-$1.12M-$0.76N/AN/AN/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.17M-$1.22N/AN/AN/A-10.33%-21.41%-6.08%11/16/2026 (Estimated)
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-$18.21M-$2.79N/AN/AN/AN/A-145.40%-91.11%N/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$570K$0.02109.50N/AN/A-6.64%-1.09%-0.78%11/17/2026 (Estimated)

Latest SNOA, OPTH, TVRD, and TXMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-$0.65-$0.69-$0.04-$0.69N/AN/A
8/11/2026Q2 2026
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$6.1250$0.01+$6.1350$0.01$19.77 million$0.87 million
8/6/2026Q1 2027
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.30$0.02+$0.32-$0.09$4.99 million$6.41 million
6/16/2026Q4 2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.24-$0.33-$0.09-$0.33$5.57 million$5.56 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
OPTH
Optimi Health
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
OPTH
Optimi Health
0.04
0.06
0.03
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
2.99
2.29
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/A
1.87
1.87
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A
3.22
3.22

Institutional Ownership

CompanyInstitutional Ownership
OPTH
Optimi Health
N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
44.66%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
30.74%

Insider Ownership

CompanyInsider Ownership
OPTH
Optimi Health
N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.02%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
7.40%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
1.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
OPTH
Optimi Health
N/A5.73 millionN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1804.79 million4.74 millionNot Optionable
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
8013.34 million12.35 millionN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
42011.57 million11.38 millionOptionable

Recent News About These Companies

Critical Contrast: Nutriband (NASDAQ:NTRB) versus TherapeuticsMD (NASDAQ:TXMD)
September 16 at 2:48 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31026012
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gains
June 5, 2026  |  marketwatch.comhttps://www.marketwatch.com/data-news/therapeuticsmd-inc-stock-underperforms-thursday-when-compared-to-competitors-despite-daily-gains-e98194d4-63e529e0f496
TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives
May 12, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/therapeuticsmd-reports-quarterly-profit-evaluates-strategic-alternatives?utm_source=marketbeat.com&utm_medium=referral
TherapeuticsMD Announces First Quarter 2026 Financial Results
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512202804/en/therapeuticsmd-announces-first-quarter-2026-financial-results/
TherapeuticsMD Inc. stock outperforms competitors on strong trading day
April 6, 2026  |  marketwatch.comhttps://www.marketwatch.com/data-news/therapeuticsmd-inc-stock-outperforms-competitors-on-strong-trading-day-040b2196-45a687e58918
TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy
April 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TXMD/pressreleases/1078704/therapeuticsmd-narrows-2025-loss-advances-royalty-strategy/
TherapeuticsMD Explains Brief Delay In Annual Filing
April 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/therapeuticsmd-explains-brief-delay-in-annual-filing?utm_source=marketbeat.com&utm_medium=referral
TherapeuticsMD Announces Full Year 2025 Financial Results
March 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/therapeuticsmd-announces-full-2025-financial-200500867.html
TherapeuticsMD Announces Full Year 2025 Financial Results
March 30, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260330300354/en/therapeuticsmd-announces-full-year-2025-financial-results/
TherapeuticsMD (NASDAQ:TXMD) Director Tommy Thompson Buys 8,400 Shares
December 30, 2025  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-txmd-insider-buying-and-selling-2025-12-30/
TherapeuticsMD approves key proposals at annual meeting
December 16, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/therapeuticsmd-approves-key-proposals-at-annual-meeting/ar-AA1Su8Dj
TherapeuticsMD: Q3 Earnings Snapshot
November 13, 2025  |  timesunion.comT
TherapeuticsMD Reports Q3 2025 Financial Results
November 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/therapeuticsmd-reports-q3-2025-financial-results/ar-AA1QnC2D
TherapeuticsMD Announces Third Quarter 2025 Financial Results
November 12, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251112021883/en/therapeuticsmd-announces-third-quarter-2025-financial-results/
TherapeuticsMD Reports Q2 2025 Financial Results
August 12, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/therapeuticsmd-reports-q2-2025-financial-results/ar-AA1KpHMy
TherapeuticsMD: Q2 Earnings Snapshot
August 12, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/therapeuticsmd-q2-earnings-snapshot-204721737.html
TherapeuticsMD Announces Second Quarter 2025 Financial Results
August 12, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250811851819/en/therapeuticsmd-announces-second-quarter-2025-financial-results/
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gains
July 16, 2025  |  marketwatch.comhttps://www.marketwatch.com/data-news/therapeuticsmd-inc-stock-underperforms-wednesday-when-compared-to-competitors-despite-daily-gains-58f6d45e-3192f8dc9ef2
Marlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street Journal
June 29, 2025  |  wsj.comhttps://www.wsj.com/market-data/quotes/TXMD/company-people/executive-profile/120136887
Mayne Pharma Files Legal Complaint Against TherapeuticsMD
June 1, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mayne-pharma-files-legal-complaint-against-therapeuticsmd?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Optimi Health NASDAQ:OPTH

$4.90 -0.17 (-3.35%)
As of 04:00 PM Eastern

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. Optimi Health Corp. is based in VANCOUVER, BC.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$1.23 -0.05 (-3.91%)
Closing price 04:00 PM Eastern
Extended Trading
$1.26 +0.03 (+2.44%)
As of 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Tvardi Therapeutics stock logo

Tvardi Therapeutics NASDAQ:TVRD

$1.73 -0.03 (-1.70%)
Closing price 04:00 PM Eastern
Extended Trading
$1.74 +0.01 (+0.29%)
As of 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

TherapeuticsMD stock logo

TherapeuticsMD NASDAQ:TXMD

$2.18 +0.02 (+0.93%)
As of 04:00 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas